Fully automated PCR system for COVID-19 detection
Prepare for the next COVID-19 outbreak with rapidly scalable PCR testing infrastructure.
Incorporating rapidly scalable PCR capability into laboratories will ensure testing needs can always be met, even during surges.
Current PCR-based testing efforts have been challenging to scale, often hampered by an unstable supply chain of instruments, consumables and reagents, and by PCR testing systems that can process only a few thousand tests per day.
LGC Biosearch Technologies offers SARS-CoV-2 testing technologies that offer unrivaled scalability. Our platforms comfortably bridge your lab throughput needs to meet future surge capacity with two FDA EUA solutions. One platform achieves over 35,000 completed test results per day, and our ultra-high-throughput PCR testing system is capable of processing over 100,000 test results per day.
Ready to rapidly expand testing capacity with minimal need for additional staff or lab space? Learn more about our fully automated PCR systems by selecting the throughput you’d like to process on a single system.
Enabling home access to screen asymptomatic and symptomatic individuals. Complete 5,000 test results per hour on a single system.
Highly scalable, fully automated high-throughput PCR
Biosearch Technologies’ COVID-19 PCR-based testing solutions are scalable to your desired throughput, ranging from 4,500 to 150,000 samples per day. Our high-throughput and ultra-high-throughput technologies have been used in genomics labs worldwide for over 10 years. Curious about how we’re redefining throughput for PCR-based viral detection?
Uniquely positioned to scale testing with every peak and trough
LGC’s market-leading expertise, high-quality molecular diagnostic components, and strong partner relationships has enabled the company to respond quickly to the COVID-19 pandemic since January 2020. With a history defending against public health crises such as the 2009 H1N1 Swine Flu outbreak, we are committed to being part of the worldwide solution for managing the spread of COVID-19 and beyond. Biosearch Technologies, the portfolio for genomic analysis by LGC, will allow for large-scale screening to help unlock the potential in bringing some sense of “normalcy” back into our daily activities.
LGC enables rapid, large-scale implementation of laboratory diagnostics for COVID-19 by expediting availability of mission-critical extraction chemistries, oligos, PCR reagents, quality control solutions, and instrumentation that deliver SARS-CoV-2 detection kits at scale.
LGC is proud to have worked with customers including many of the world-leading IVD companies, clinical laboratories, governments and regulatory agencies to rapidly respond to this pandemic.
Visit our COVID-19 Resources Hub